Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Scientific reports - 9(2019), 1 vom: 21. Aug., Seite 12163 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vigón, Lorena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
49717AWG6K |
|---|
| Anmerkungen: |
Date Completed 22.10.2020 Date Revised 10.01.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-019-48592-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300448082 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300448082 | ||
| 003 | DE-627 | ||
| 005 | 20231226200505.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-019-48592-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1001.xml |
| 035 | |a (DE-627)NLM300448082 | ||
| 035 | |a (NLM)31434968 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vigón, Lorena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.10.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with peg-IFNα + ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against five JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hepatitis C Antibodies |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 700 | 1 | |a Vázquez-Morón, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Berenguer, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a González-García, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Sousa, Ma Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Guardiola, Josep M |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a de Los Santos, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Von Wichmann, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Carrero, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Yélamos, María Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, Julián |e verfasserin |4 aut | |
| 700 | 1 | |a Resino, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Isidoro |e verfasserin |4 aut | |
| 700 | 0 | |a GESIDA 3603b Cohort Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Miralles, P |e investigator |4 oth | |
| 700 | 1 | |a López, J C |e investigator |4 oth | |
| 700 | 1 | |a Parras, F |e investigator |4 oth | |
| 700 | 1 | |a Padilla, B |e investigator |4 oth | |
| 700 | 1 | |a Aldamiz-Echevarría, T |e investigator |4 oth | |
| 700 | 1 | |a Tejerina, F |e investigator |4 oth | |
| 700 | 1 | |a Díez, C |e investigator |4 oth | |
| 700 | 1 | |a Pérez-Latorre, L |e investigator |4 oth | |
| 700 | 1 | |a Fanciulli, C |e investigator |4 oth | |
| 700 | 1 | |a Gutiérrez, I |e investigator |4 oth | |
| 700 | 1 | |a Ramírez, M |e investigator |4 oth | |
| 700 | 1 | |a Carretero, S |e investigator |4 oth | |
| 700 | 1 | |a Bellón, J M |e investigator |4 oth | |
| 700 | 1 | |a Bermejo, J |e investigator |4 oth | |
| 700 | 1 | |a Hontañón, V |e investigator |4 oth | |
| 700 | 1 | |a Arribas, J R |e investigator |4 oth | |
| 700 | 1 | |a Montes, M L |e investigator |4 oth | |
| 700 | 1 | |a Bernardino, I |e investigator |4 oth | |
| 700 | 1 | |a Pascual, J F |e investigator |4 oth | |
| 700 | 1 | |a Zamora, F |e investigator |4 oth | |
| 700 | 1 | |a Peña, J M |e investigator |4 oth | |
| 700 | 1 | |a Arnalich, F |e investigator |4 oth | |
| 700 | 1 | |a Díaz, M |e investigator |4 oth | |
| 700 | 1 | |a Domingo, P |e investigator |4 oth | |
| 700 | 1 | |a Sanz, J |e investigator |4 oth | |
| 700 | 1 | |a Bustinduy, M J |e investigator |4 oth | |
| 700 | 1 | |a Iribarren, J A |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez-Arrondo, F |e investigator |4 oth | |
| 700 | 1 | |a Eynde, E Van den |e investigator |4 oth | |
| 700 | 1 | |a Pérez, M |e investigator |4 oth | |
| 700 | 1 | |a Ribera, E |e investigator |4 oth | |
| 700 | 1 | |a Casado, J L |e investigator |4 oth | |
| 700 | 1 | |a Dronda, F |e investigator |4 oth | |
| 700 | 1 | |a Moreno, A |e investigator |4 oth | |
| 700 | 1 | |a Pérez-Elías, M J |e investigator |4 oth | |
| 700 | 1 | |a Sanfrutos, M A |e investigator |4 oth | |
| 700 | 1 | |a Moreno, S |e investigator |4 oth | |
| 700 | 1 | |a Quereda, C |e investigator |4 oth | |
| 700 | 1 | |a Arranz, A |e investigator |4 oth | |
| 700 | 1 | |a Casas, E |e investigator |4 oth | |
| 700 | 1 | |a Miguel, J de |e investigator |4 oth | |
| 700 | 1 | |a Schroeder, S |e investigator |4 oth | |
| 700 | 1 | |a Vergas, J |e investigator |4 oth | |
| 700 | 1 | |a Téllez, M J |e investigator |4 oth | |
| 700 | 1 | |a Vinuesa, D |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, L |e investigator |4 oth | |
| 700 | 1 | |a Hernández-Quero, J |e investigator |4 oth | |
| 700 | 1 | |a Ferrer, A |e investigator |4 oth | |
| 700 | 1 | |a Galindo, M J |e investigator |4 oth | |
| 700 | 1 | |a Ortiz, L |e investigator |4 oth | |
| 700 | 1 | |a Ortega, E |e investigator |4 oth | |
| 700 | 1 | |a Montero, M |e investigator |4 oth | |
| 700 | 1 | |a Blanes, M |e investigator |4 oth | |
| 700 | 1 | |a Cuellar, S |e investigator |4 oth | |
| 700 | 1 | |a Lacruz, J |e investigator |4 oth | |
| 700 | 1 | |a Salavert, M |e investigator |4 oth | |
| 700 | 1 | |a López-Aldeguer, J |e investigator |4 oth | |
| 700 | 1 | |a Pérez, G |e investigator |4 oth | |
| 700 | 1 | |a Gaspar, G |e investigator |4 oth | |
| 700 | 1 | |a Yllescas, M |e investigator |4 oth | |
| 700 | 1 | |a Crespo, P |e investigator |4 oth | |
| 700 | 1 | |a Aznar, E |e investigator |4 oth | |
| 700 | 1 | |a Esteban, H |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 9(2019), 1 vom: 21. Aug., Seite 12163 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2019 |g number:1 |g day:21 |g month:08 |g pages:12163 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-019-48592-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2019 |e 1 |b 21 |c 08 |h 12163 | ||